A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients

British Journal of Haematology

Volumn 154, Issue 1, 2011, Pages 104-110

  Sher, Taimur ^a   Ailawadhi, Sikander ^b   Miller, Kena C ^a   Manfredi, Debbie ^a   Wood, Margaret ^a   Tan, Wei ^a   Wilding, Gregory ^a   Czuczman, Myron S ^a   Hernandez Ilizaliturri, Francisco J ^a   Hong, Fredrick ^c   Sood, Raman ^c   Soniwala, Saif ^c   Lawrence, William ^c   Jamshed, Saad ^c   Masood, Aisha ^a   Iancu, Daniel ^a   Lee, Kelvin ^a   Chanan Khan, Asher ^a,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Western New York Myeloma Research Network   (United Kingdom)

Author keywords

Clinical trials; Multiple myeloma; Newly diagnosed multiple myeloma; Steroids; Thalidomide

Indexed keywords

BORTEZOMIB; DOXORUBICIN; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; BRADYCARDIA; CANCER GROWTH; CLINICAL ARTICLE; CONFUSION; CONGESTIVE HEART FAILURE; CONSTIPATION; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; INFECTION; INTERSTITIAL PNEUMONIA; LUNG EMBOLISM; LUNG INSUFFICIENCY; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; SENSORY NEUROPATHY; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VENOUS THROMBOEMBOLISM;

EID: 79958789571     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08703.x     Document Type: Article

References (17)

1. Alexanian, R., Dimopoulos, M., Delasalle, K. & Barlogie, B. (1992) Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887-890.
2. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
3. Chanan-Khan, A., Miller, K.C., Musial, L., Padmanabhan, S., Yu, J., Ailawadhi, S., Sher, T., Mohr, A., Bernstein, Z.P., Barcos, M., Patel, M., Iancu, D., Lee, K. & Czuczman, M.S. (2009) Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukaemia & Lymphoma, 50, 1096-1101.
4. D'Amato, R.J., Lentzsch, S., Anderson, K.C. & Rogers, M.S. (2001) Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Seminars in Oncology, 28, 597-601.
5. Hsu, A.K., Quach, H., Tai, T., Prince, H.M., Harrison, S.J., Trapani, J.A., Smyth, M.J., Neeson, P. & Ritchie, D.S. (2011) The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood, 117, 1605-1613.
6. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. & Thun, M.J. (2008) Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58, 71-96.
7. Ma, M.H., Yang, H.H., Parker, K., Manyak, S., Friedman, J.M., Altamirano, C., Wu, Z.Q., Borad, M.J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R.A. & Berenson, J.R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 9, 1136-1144.
8. Miller, K.C., Padmanabhan, S., Dimicelli, L., Depaolo, D., Landrigan, B., Yu, J., Doran, V., Marshal, P. & Chanan-Khan, A. (2006) Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leukaemia & Lymphoma, 47, 2339-2343.
9. Orlowski, R.Z., Voorhees, P.M., Garcia, R.A., Hall, M.D., Kudrik, F.J., Allred, T., Johri, A.R., Jones, P.E., Ivanova, A., Van Deventer, H.W., Gabriel, D.A., Shea, T.C., Mitchell, B.S., Adams, J., Esseltine, D.L., Trehu, E.G., Green, M., Lehman, M.J., Natoli, S., Collins, J.M., Lindley, C.M. & Dees, E.C. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, 3058-3065.
10. Orlowski, R.Z., Nagler, A., Sonneveld, P., Blade, J., Hajek, R., Spencer, A., San Miguel, J., Robak, T., Dmoszynska, A., Horvath, N., Spicka, I., Sutherland, H.J., Suvorov, A.N., Zhuang, S.H., Parekh, T., Xiu, L., Yuan, Z., Rackoff, W. & Harousseau, J.L. (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of Clinical Oncology, 25, 3892-3901.
11. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431-436.
12. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology, 11, 29-37.
13. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487-2498.
14. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906-917.
15. Schafer, P.H., Gandhi, A.K., Zhang, L.-H., Kang, J., Capone, L., Parton, S., Wu, L. & Bartlett, B. (2008) Opposing effects of dexamethasone on lenalidomide activity in multiple myeloma: additive/synergistic effects on anti-proliferative activity on myeloma cells and antagonistic effects on immune function. ASH Annual Meeting Abstracts, 112, 2761.
16. Urashima, M., Chen, B.P., Chen, S., Pinkus, G.S., Bronson, R.T., Dedera, D.A., Hoshi, Y., Teoh, G., Ogata, A., Treon, S.P., Chauhan, D. & Anderson, K.C. (1997) The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow. Blood, 90, 754-765.
17. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England journal of medicine, 357, 2133-2142.